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Abstract
Background: Congenital afibrinogenemia (OMIM #202400) is a rare coagulation disorder that was first described in
1920. It is transmitted as an autosomal recessive trait that is characterized by absent levels of fibrinogen (factor I) in
plasma. Consanguinity in Pakistan and its neighboring countries has resulted in a higher number of cases of congenital
fibrinogen deficiency in their respective populations. This study focused on the detection of mutations in
fibrinogen genes using DNA sequencing and molecular modeling of missense mutations in all three genes
[Fibrinogen gene alpha (FGA), beta (FGB) and gamma (FGG)] in Pakistani patients.
Methods: This descriptive and cross sectional study was conducted in Karachi and Lahore and fully complied with the
Declaration of Helsinki. Patients with fibrinogen deficiency were screened for mutations in the Fibrinogen alpha (FGA),
beta (FGB) and gamma (FGG) genes by direct sequencing. Molecular modeling was performed to predict the putative
structure functional impact of the missense mutations identified in this study.
Results: Ten patients had mutations in FGA followed by three mutations in FGB and three mutations in FGG, respectively.
Twelve of these mutations were novel. The missense mutations were predicted to result in a loss of stability because
they break ordered regions and cause clashes in the hydrophobic core of the protein.
Conclusions: Congenital afibrinogenemia is a rapidly growing problem in regions where consanguinity is frequently
practiced. This study illustrates that mutations in FGA are relatively more common in Pakistani patients and molecular
modeling of the missense mutations has shown damaging protein structures which has profounding effect on
phenotypic bleeding manifestations in these patients.
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Background
Hemostasis is the normal physiological response that pre-
vents blood loss following vascular injury. It is dependent
on an intricate series of events involving platelets and spe-
cific coagulation factors. Inherited bleeding disorders can
be grouped into abnormalities of primary and secondary
hemostasis. Fibrinogen (Factor I) deficiency can originate
from congenital or acquired causes. Congenital afibrino-
genemia (OMIM #202400) is a rare coagulation disorder
that was first described in 1920 [1]. It is as a recessive
autosomal inherited trait characterized by the absence of
fibrinogen (factor I) in plasma [2]. The disease has a
worldwide prevalence of 1–2 per million in the general
population [3]. Fibrinogen is a 340 KDa hexameric protein
of hepatic origin with multiple functions including roles in
platelet aggregation and platelet plug formation and is an
acute phase reactant [4]. It is secreted as zymogen similar
to all other clotting factors and needs to be activated prior
to its participation in the coagulation cascade. It consist of
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three pairs (Aα, Bβ and Gγ) of polypeptide chains [5]
encoded by three genes (FGA, FGB and FGG) clustered in
a region of approximately 50 kb on chromosome 4q28-
q31 [6, 7]. The normal plasma levels of fibrinogen are
4 g/l [8, 9] and its half-life is approximately 100 h/4 days
[10]. The main role of fibrinogen in hemostasis is to
strengthen the platelet plug by converting into its poly-
meric insoluble form called fibrin by thrombin [11]. The
fibrin meshwork traps red blood cells and platelets to
form a plug which stops bleeding from site of injury. The
absence of fibrinogen may result in excessive blood loss
after a trauma. Moreover spontaneous bleeding events
can occur. Fibrinogen defects are classified as quantitative
(Hypofibrinogenemia and Afibrinogenemia, depending
upon the partial or complete absence of fibrinogen) or
qualitative (Dysfibrinogenemia and Hypodysfibrinogen-
emia) [12]. The most common symptom associated with
fibrinogen deficiency is umbilical stump bleeding with
other secondary bleeding manifestations including epi-
staxis, gum bleeding, cutaneous bleeding, muscle
hematoma and haemarthrosis [13].
Congenital fibrinogen deficiency is considered as
rare coagulation disorder but its incidence is growing
higher in those regions where consanguineous partner-
ships are common [14, 15]. Pakistan is the country
with high ratio of consanguinity resulting in increasing
numbers of rare inherited bleeding disorders including
congenital afibrinogenemia. Our focus was to identify
the mutations, assess the possible structure functional
impact of affected protein by using molecular model-
ing/silico analysis tools. In addition to this, the study
also encompasses the insight for possible mutational
spectrum in frequently involved fibrinogen gene which
may contribute for future prenatal diagnosis of carriers of
these defects in Pakistani population.
Methods
Patient inclusion and exclusion criteria
This study, involving human subjects, was performed ac-
cording to the Declaration of Helsinki, 1975, revised in
2000, and was approved by the relevant institutional
Ethical Committee. Patients with congenital afibrinoge-
nemia i.e. absent or undetectable levels of fibrinogen
antigen (0–0.1 g/dl) and it activity in plasma were se-
lected for this study. These low levels excluded acquired
causes of fibrinogen deficiency, such as liver disease and
consumptive coagulopathies, leukemia or other factor
deficiencies. Patients from across Pakistan were re-
cruited from centers including Karachi (Sindh) and
Lahore (Punjab). A written informed consent was taken
from patients and guardians incase of minor. Sampling
was performed independent of sex or age. A comprehen-
sive questionnaire was completed containing informa-
tion about the patient’s demographics and disease
symptoms. A diagnosis was made on the basis of history
and quantitative analysis. All subjects were registered at
Hemophilia Society of Pakistan. Samples from all centers
were collected and initially processed and saved at the
National Institute of Blood Diseases (NIBD) for coagula-
tion profile, biochemistry tests including liver profile and
viral markers. DNA sequencing was performed in NIBD
genome department, Karachi.
Sample collection and lab assays
Blood samples from patients were collected in 3.2% so-
dium citrate for coagulation profile in serum (RST) for
biochemistry analysis, including liver profile and viral
profile, (HBsAg, Anti HCV and HIV) and in K2EDTA
for complete blood count and DNA extraction for amp-
lification and sequencing. All sampling was performed
with supportive infusion of cryoprecipitate to avoid
bleeding. Platelet-poor plasma was collected by centri-
fugation of citrate tubes at 4000×g for 10 min and co-
agulation profile was performed, including PT, APTT
and fibrinogen assay, using the Clauss method. Liver
function tests (direct and indirect bilirubin, ALT, AST
and alkaline phosphatase) and viral markers (HBsAg,
anti HCV and HIV) were performed to exclude any ac-
quired cause of afibrinogenemia.
Genetic analysis was performed after isolation of geno-
mic DNA using standard protocols, exons and intron-
exon junctions of the fibrinogen genes were amplified by
polymerase chain reaction [16] and sequenced [17] as
previously described.
Pathogenecity scoring
Pathogenecity scoring was done by five prediction tools
to predict the possible structure functional impact of af-
fected protein in identified novel missense mutations.
The prediction software tool Poly-phen2 (polymorphism
phenotyping v2), (http://genetics.bwh.havard.edu/pph2/
accessed on 20th April 2015) was used to assess the pos-
sible impact of substitution on structure and function in
human SNPs (Single nucleotide polymorphism). MUPRO
(predictions of protein stability changes upon mutations),
(http://mupro.proteomics.ics.uci.edu/ accessed on 20th
April 2015) utilizes an SVM (support vector machines)
model to predict the changes in stability as a result of
single-site mutations, primarily from sequential informa-
tion, and optionally provided structural information. The
result only predicts whether the alteration in single amino
acid will lead to destabilization or not. MUPRO predic-
tions are reported with the confidence score (C score). A
positive score indicates higher stability whereas a negative
score shows the mutation decreases the protein stability
(http://mupro.proteomics.ics.uci.edu/ accessed on 20th
April 2015). SNP&GO (Single nucleotide polymorphism
and GO terms, http://snps.biofold.org/snps-and-go
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accessed on 20th April 2015). SIFT (Sorting Intolerant
from Tolerant, http://sift.jcvi.org accessed 20th April 2015)
are algorithms which predict whether an amino acid substi-
tution will affect protein function based on sequence hom-
ology and the physical properties of amino acids. A SIFT
score of less than 0.05 is predicted to be deleterious. A sub-
stitution with a score greater than or equal to 0.05 is pre-
dicted to be tolerated (http://www.exeterlaboratory.com/
molecular-genetics/). Provean (http://provean.jcvi.org/
about.php) accessed on 27th January 2015) has the default
threshold of −2.5 that means if the score of a variant is
equal or below this threshold then the mutation is said to
be deleterious and if the threshold is above −2.5, the score
of variant is said to have neutral effects. Protein accession
numbers were provided by Uniprot (Universal Protein
Resource, http://www.uniprot.org/) and wild type color
fasta sequence was first accessed (http://pga.gs.washingto-
n.edu/data/fga/fga.Colorfasta.html) on 27th January 2015
and later on 20th April 2015.
Structural analysis of novel missense mutations using
molecular modeling
Among the six reported novel missense mutations from
this study, four mutations were located in an area of the
alpha chain that has no resolved crystal/NMR-based
structure (Nuclear magnetic Resonance). Thus, to assess
the putative structural effect of these mutations, we mo-
deled this region on the ITASSER (Iterative Threading
ASSEmbly Refinement) threading modeling server (http://
zhanglab.ccmb.med.umich.edu/I-TASSER/; accessed on
12th November 2014). The model for this region was then
joined to the remaining beta chain for which the structure
has already been determined and submitted in the protein
structure database (PDB file ID: 3GHG; 2.9 Å resolution).
Model joining was performed by replacing the last two
amino acid residues common to the model and the crystal
structure (PDB file ID: 3GHG; chain A) (PDB: Protein
Data Base, ID: Identity, 3ghg is a 4-character unique iden-
tifier of every entry in the Protein Data Bank) downloaded
from the protein structure database (http://rcsb.org/pdb/
home/home.do;) accessed 20th November 2014) to main-
tain the dihedral angles for the full model at the point of
joining the same. The complete model was refined by a
short solvated simulation lasting 500 ps as described in
Krieger et al., 2004 (Force field: Yamber3, periodic boun-
dary conditions, temperature: 298 K, water density:
0.997 g/L, pH: 7.4). The local neighborhood of the wild
type residue corresponding to the reported mutation was
investigated to establish a logical hypothesis for the effect
of the mutation. An additional one missense mutations
(p.Trp432Arg) in the beta chain lies on the structurally
resolved region of the PDB file 3GHG; chain B). Simi-
larly the local molecular environment for this wild-type
residue was also inspected. All structural analysis and
image rendering were performed with YASARA (Yet
Another Scientific Artificial Reality Application) version
12.8.6 (www.yasara.org/).
Results
Mutations were identified in all 13 patients. The major
bulk of identified mutations is present in FGA gene
which tends to be the most frequently occurring mu-
tation site in our study population. Ten patients who
have mutations in FGA gene are individual unrelated
probands.
Mutations in FGB gene are less frequent as compared
to FGA.
In FGA gene, eight mutations were identified as novel
and the remaining two were reported mutations. Eight
novel mutations include five missense, one nonsense
and two frameshift mutations including homozygous
and a compound heterozygous frameshift mutation. The
two nonsense mutations in FGA are reported in litera-
ture. There is one more mutation with reported status in
proband (C3). This patient had compound heterozygous
mutation with frameshift as novel mutation and non-
sense as reported.
We identified three mutations in FGB including one
novel missense mutation (C9) and two homozygous
nonsense mutations reported in siblings.
The FGG gene mutations are the rarest of all three
fibrinogen genes. We detected three novel mutations
including two similar nonsense mutations in siblings
and one frameshift mutation in unrelated proband in
different exons of FGG gene (Table 1).
All patients had markedly absent fibrinogen levels (0 g/l)
and prolonged PT >120 s and APTT >180 s (Table 2).
Structural analysis of novel missense mutations using
molecular modeling
A) alpha chain missense mutations
All four novel missense mutations from the α-chain re-
ported in this study were present in a region (residues
220–860) of the α-chain, which had no resolved/known
crystal structure. The region surrounding the reported
mutations (residues 300–400) was relatively poorly con-
served with most of it missing from some fibrinogen
homologues.
Among the mutated residues, p.Pro302 was present in
all homologues, which contained this part. The p.Ser325
residue was also conserved in all homologues with the
exception of Musmusculus, where it was substituted by
an Asn. The two Thr residues, p.Thr302 and p.Thr331,
were relatively variable and substituted by Ser or Asp in
a few homologues. Only in the homologue from Canis
lupus familiaris was one of the Thr residues (p.Thr302)
observed to be substituted by an Ala residue, which has
been reported as a mutated residue for both Thr
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Table 1 Genotypic expression of mutations in fibrinogen gene (FGA, FGB & FGG)
IP # Gene Exon Mutation Amino Acid change Zygosity Mutation type Reported/Novel
C1 FGA 1 c.24C > A p.Cys8a Homozygous Nonsense Ref [23] €
C2 2 c.143_144 del AA p.Lys(AAA)48Arg fs9a Compound Heterozygous Frame shift Novel mutation
C3 5 c.846delG p.Gln282Thr fsx83a Compound Heterozygous Frame shift Novel mutation
4 c.385C > T p.Arg129a Homozygous Nonsense Ref [24] €
C4 4 c.385 C > T p.Arg129a Homozygous Nonsense Ref [24] €
C5 5 c.598C > T p.Gln183a Homozygous Nonsense Novel mutation
C6 5 c.904C > G p.Pro302Ala Homozygous Missense Novel mutation
C7 5 c.913A > G p.Thr 305 Ala Homozygous Missense Novel mutation
C8 5 c.992A > G p.Thr331Ala Homozygous Missense Novel mutation
C9 5 c.992A > G p.Thr331Ala Homozygous Missense Novel mutation
C10 5 c.974A > G p.Ser325Gly Homozygous Missense Novel mutation
C11A FGB 2 c.141 > T p.Arg47a Homozygous Nonsense Ref [25] €
C11B 2 c.141C > T p.Arg47a Homozygous Nonsense Ref [25] €
C9 8 c.1294 T > A p.Trp 432Arg Homozygous Missense Novel mutation
C12 FGG 2 c.120_126dupTTCTTCA TTCTTCA Homozygous Frame shift Novel mutation
C13A 4 c.361A > T p.Lys121a Homozygous Nonsense Novel mutation
C13B 4 c.361A > T Lys121a Homozygous Nonsense Novel mutation
Identified novel and reported mutations in three genes of fibrinogen. The letter A and B with patient code designate the sibling status. € (reported mutation,) c
(complimentary deoxyribonucleic acid), A (adenine), T (thymine), C (cytosine), G (guanine), Lys (lysine), Arg (arginine), Tyr (tyrosine), Pro (proline), Trp (tryptophan), Thr (threonine),
Gln (glycine), Cys = cystine, fs = frame shift, a stop codon number, FGA (fibrinogen Aα-chain gene), FGB (fibrinogen Bβ-chain gene), FGG (fibrinogen GƔ-chain gene















C1 0.01 23 >120 >180 20 positive Unrelated Urdu
Speaking
C2 0.02 24 >120 >180 21 positive Unrelated Punjabi
C3 0 33 >120 >180 22 positive Unrelated Punjabi
C4 0.1 24 >120 >180 17 positive Unrelated Urdu
Speaking
C5 0.02 31 >120 >180 20 positive Unrelated Sindhi
C6 0.01 25 >120 >180 20 positive Unrelated Urdu
speaking
C7 0.02 29 >120 >180 22 positive Unrelated Sindhi
C8 0.0 30 >120 >180 20 positive Unrelated Sindhi
C9 0.0 32 >120 >180 22 positive Unrelated Punjabi
C10 0.01 25 >120 >180 16 positive Unrelated Punjabi
C11A 0.02 28 >120 >180 18 positive ** Punjabi
C11B 0.01 24 >120 >180 16 positive Punjabi
C12 0.0 30 >120 >180 21 positive Unrelated Punjabi
C13 0.01 24 >120 >180 20 positive Unrelated Punjabi
C14 0.0 26 >120 >180 21 positive Unrelated Punjabi
C15A 0.02 24 >120 >180 20 positive ** Punjabi
C15B 0.01 25 >120 >180 21 positive Punjabi
Shows the individual test values of PT, aPTT and fibrinogen (Claus Method), consanguinity and the relationship status. Bleeding score calculated, Tosetto et al.
[26]. ** Siblings, NA not available, s (seconds). The fibrinogen levels in all patients were found to be equal to or lower than 0.1 g/l (Normal Range 2-4 g/dl), PT
more than 120 s (Normal Range 9–11 s) aPTT more than 180 s (Normal Range 24–27 s) and prolonged thrombin time (normal range 10–13 s). Ethnicity explains
the frequency of majorly affected, thickly populated and largest province of Pakistan (Punjab)
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residues in our study. Modeling of this region showed
that this region could be split into two central cores,
each of which is organized as a beta sheet surrounded
by flexible coils (Fig. 1). The two cores are connected by
a central long helix. The first core, apart from being sur-
rounded by flexible coils, also contains a few short heli-
ces. Three of the four reported mutated residues were
located on these short helices with the exception that
p.Ser325 is located on a short loop connecting one of
the short helices to the central core. The residues
p.Pro302, p.Thr305 and p.Thr331 are partially buried,
with the p.Pro302 and p.Thr305 side chains oriented to-
ward the central core beta sheets. The residues p.Pro302
and p.Thr305 participate in intra-helical hydrogen bonds
with each other and with p.Ser399 and p.Arg308, re-
spectively. The residue p.Thr331 lies at the edge of a
short helix and also participates in intra-helical hydrogen
bonding (p.Gly327). Interestingly, within the fold on
which all four of these mutations reside, lysine residue
p.Lys322 is known to be cross-linked to ∝ − 2 antiplas-
min proteins and a glutamine residue, p.Gln347, which
participates in inter-chain cross-links during clot
formation.
B) Beta chain missense mutations
The one novel missense mutations (p.Trp432Arg) reported
in the chain occurs in a highly conserved region. (Fig. 2).
The residues are completely conserved in homo-
logues that have been used for the present alignment.
The p.Trp432 residue lies completely in the densely
packed hydrophobic core of the C-terminal region of
chain. This densely packed hydrophobic core consists
of a number of other aromatic acids, which are in close
proximity to p.Trp432 (p.His400 and p.His438,
p.Trp433 and p.Tyr434). The p.Trp432 residue hydro-
gen bond contacts with p.Tyr434 and p.Ser406.
Pathogenecity score
Pathogenecity scoring of six novel missense mutations
identified in FGA and FGB was done on five different
pathogenicity scoring software (Table 3). Out of five mis-
sense mutations of FGA, two mutations were found to
have damaging effect and decreased protein stability cal-
culated by two different softwares (MUPRO and Provean).
Other software didn’t show the deleterious effect for the
same two mutations identified in two unrelated proband.
In FGB gene the missense mutation was found to be
damaging or deleterious and showed decreased structure
stability. The damaging effect and lack of protein stability
in structure may lead to the bleeding manifestations in
patients which can vary from mild to severe bleeding.
Discussion
Fibrinogen deficiency is a rare inherited bleeding disorder
that is characterized by two subtypes of either reduced or
completely absent levels of fibrinogen in the blood [18].
FGA is documented as the most affected gene in literature
[19, 20]. We have found the larger chunk of mutations in
FGA gene in our set of data. A total of 169 mutations in fi-
brinogen are reported on the Human Gene Mutation
Database (http://www.hgmd.cf.ac.uk/ac/index.php) date
accessed August 12, 2014). Consanguinity involving
Fig. 1 Molecular Remodeling of a missense mutation in FGA
Naz et al. Thrombosis Journal  (2017) 15:24 Page 5 of 8
first and second cousin marriages is accelerating the
spread of disease in areas such as Pakistan, Iran, the
Middle East, China and the far Middle East, including
Turkey, in societies where consanguinity is frequent.
The spectrum of causative mutations for afibrinoge-
nemia is interesting as FGA appears to stand out from
the two other fibrinogen genes [21]. The predominant
inheritance pattern was homozygous with a high pro-
portion of nonsense mutations followed by missense
mutations in our study results. A frame shift mutation
(p.Glu262AspfsX158) in FGA exon 5 reported in one
study is predicted as truncated polypeptide. It is as-
sociated with exceptionally long stretch of abnormal
residues in homozygous patient with congenital afi-
brinogenemia [22]. Frameshift mutation (p.Gln282Thr
fsx83*) and (p. Lys (AAA) 48Arg fs9*) are the novel
compound heterozygous mutations which have mani-
fested deletions along with frameshift defects. The
Fig. 2 Molecular Remodeling of a missense mutation in FGB
Table 3 Pathogenicity score of missense mutations
Missense
Mutations
Polyphen- 2 Provean MUpro SNP&GO Sift
Score prediction Score prediction SVM score Protein structure stability Score Prediction Score Prediction
p.Pro302Ala 0.028 Benign −4.257 Deleterious −0.797 Decrease stability (0.4) Neutral 0.00 Benign
p.Thr 305 Ala 0.00 Benign −0.387 Neutral 0.134 Increase stability (0.05) Neutral 0.00 Benign
p.Thr331Ala 0.025 Benign −1.100 Neutral 0.122 Increase stability (0.03) Neutral 0.00 Benign
p.Thr331Ala 0.025 Benign −1.100 Neutral 0.122 Increase stability (0.03) Neutral 0.00 Benign
p.Ser325Gly 0.014 Benign −2.331 Neutral −0.063 Decrease stability (0.1) Neutral 0.00 Benign
p.Trp 432Arg 1.00 Damaging −12.18 Deleterious −0.411 Decrease stability (0.8) Disease Na Na
Pathogenecity of missense mutations was calculated by five different softwares to check for the protein structure stability and deleterious effects. Na not available
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bleeding phenotype is severe as these mutations worsen
the symptoms due to combined effect of compound
mutation and truncation of polypeptide chain.
Three missense mutations (Pro302Ala, Thr305Ala and
Thr331Ala) in the alpha chain reside on short helices
surrounding a central beta sheet core. All these muta-
tions are non-conservative in nature, i.e., the Pro302Ala
substitution results in the replacement of a rigid imino
group with a smaller, more flexible residue, and the
Thr305Ala and Thr302Ala substitutions result in the re-
placement of polar side chains by smaller but hydropho-
bic side chains. In addition, the introduction of alanine
in these regions will most likely disrupt some of the
intra-helical hydrogen bonds, thereby breaking the he-
lical structure surrounding the central core. Because
these short helices provide order and stability around an
otherwise disordered coiled-coil region, their disruption
might result in a loss of stability for this region and the
alpha chain. The third mutation in this chain, Ser325Gly,
is also non-conservative, i.e., it results in the substitution
of a polar residue to a very small and flexible Gly resi-
due. Because the wild-type residue already lies on the
flexible loop, the introduction of a small residue will
make this region more disordered and therefore un-
stable. Moreover, because all four missense mutations
belong to a fold of the alpha chain that might be inter-
acting with Factor XIII (this fold also contains the Lys
and Gln residues that participate in interchain cross
linking and cross linking to alpha 2- antiplasmin), con-
formational changes induced by these mutations on this
fold might interfere with the interaction of fibrinogen
alpha chain with Factor XIII. The one beta chain mis-
sense mutation resides on a highly conserved region of
the beta chain, most likely because many of the residues
of this region contribute to the stability of its densely
packed hydrophobic core. The p.Trp432Arg substitution
occurs in the middle of the hydrophobic core. The intro-
duction of a large polar, positively charged residue ins-
tead of a hydrophobic aromatic one would destabilize
the hydrophobic core of this region. Thus, the mutation
affects the stability of the beta chain by disrupting its
C-terminal hydrophobic core.
Conclusions
Rare inherited bleeding disorder specifically congenital
afibrinogenemia has a growing incidence especially in
regions like Pakistan where consanguinity factor is
strongly present. Our study is purely based on Pakistani
patients of congenital afibrinogenemia. It has shown the
frequently affected gene FGA in our set of patients. We
have documented the pathogenicity scores for missense
mutations as a description for protein molecule stability
and functional defects. We have also performed molecu-
lar modeling to see the structural defects and damages
and their impact on the clinical manifestation of pa-
tients. In this way the genotype well correlated with
phenotype of these patients.
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